8-K: Sangamo's Fabry Gene Therapy Shows Positive Phase 1/2 Data

Sangamo Therapeutics announced positive clinical data from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec, a gene therapy for Fabry disease, supporting an Accelerated Approval pathway.

Summary

• Clinical data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec (ST-920), a wholly-owned gene therapy for Fabry disease, was presented at the 22nd Annual WORLD Symposium™.
• The data cutoff date was April 10, 2025, encompassing 33 treated patients, with 32 patients having completed 52 weeks of follow-up and successfully rolled into a long-term follow-up study.
• The U.S. Food and Drug Administration (FDA) has provided a clear regulatory pathway, agreeing that data from the Phase 1/2 STAAR study can serve as the primary basis for approval under the Accelerated Approval Program, using mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks as an intermediate clinical endpoint.
• A rolling submission of a Biologics License Application (BLA) to the FDA seeking approval of isaralgagene civaparvovec under an Accelerated Approval pathway was initiated in December 2025.
• Isaralgagene civaparvovec was generally well-tolerated across all dose cohorts without the need for preconditioning, with the majority of adverse events (AEs) being mild (Grade 1) or moderate (Grade 2).
• Positive mean annualized eGFR slopes of 1.965 mL/min/1.73m²/year (95% CI: -0.153, 4.083) at 52 weeks and 1.747 mL/min/1.73m²/year (95% CI: -0.106, 3.601) at 104 weeks were observed across dosed patients, comparing favorably to approved Fabry treatments.
• All 15 ERT-naïve or pseudo-naïve patients showed normal to supraphysiological levels of alpha-galactosidase A (α-Gal A) activity up to 54 months, accompanied by reduction and/or long-term stabilization of lyso-Gb3 levels.
• 17 of 18 patients who began the study on enzyme replacement therapy (ERT) showed sustained elevated levels of α-Gal A activity, and all 18 were able to safely withdraw from ERT, with one patient off ERT for more than four years.
• Significant improvements were observed in disease severity (FOS-MSSI score), quality of life (SF-36 scores for general health, physical component, bodily pain, role-physical, vitality, and social functioning), and gastrointestinal symptoms (GSRS and Diarrhea scores).
• Antibodies against α-Gal A decreased markedly in 9 patients and became undetectable in 8 (80%) of patients who had measurable titers at baseline, and treatment did not induce anti-α-Gal A antibodies in baseline seronegative patients.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, with strong clinical data supporting a gene therapy for Fabry disease and a clear regulatory path towards accelerated approval, despite inherent risks in clinical development and commercialization.

Positives

• Isaralgagene civaparvovec was generally well-tolerated across all dose cohorts without preconditioning.
• The majority of adverse events (AEs) were graded as mild (Grade 1) or moderate (Grade 2), with no AEs leading to study discontinuation and no deaths reported.
• All 15 ERT-naïve or pseudo-naïve patients showed normal to supraphysiological levels of α-Gal A activity up to 54 months.
• Sustained normal to supraphysiological expression of α-Gal A activity was accompanied by the reduction and/or long-term stabilization of lyso-Gb3 levels.
• 17 of 18 ERT-treated patients showed sustained elevated levels of α-Gal A activity.
• All 18 patients who came into the study on ERT were able to safely withdraw from ERT, with one patient now off ERT for more than four years.
• Positive mean annualized eGFR slopes of 1.965 mL/min/1.73m²/year at 52 weeks and 1.747 mL/min/1.73m²/year at 104 weeks were observed, comparing favorably to a meta-analysis of approved Fabry treatments.
• Improvements in eGFR slope were seen as early as Week 24, becoming positive at Week 36, and reaching a maximum mean eGFR slope of 3.016 mL/min/1.73m²/year at 18 months.
• Stable cardiac function was observed over 52 weeks, including stable ECG, echocardiogram, and cardiac MRI findings, with QTc interval slightly improved and ventricular wall thickness remaining stable.
• Significant improvements in disease severity (FOS-MSSI score), quality of life (SF-36 scores), and gastrointestinal symptoms (GSRS and Diarrhea scores) were reported.
• Total antibodies (TAbs) or neutralizing antibodies (NAbs) against α-Gal A decreased markedly in 9 patients and became undetectable in 8 (80%) of patients who had measurable titers at baseline.
• Treatment did not induce anti-α-Gal A antibodies in baseline seronegative patients.
• The FDA has provided a clear regulatory pathway, agreeing that Phase 1/2 STAAR study data can serve as the primary basis for approval under the Accelerated Approval Program.
• A rolling Biologics License Application (BLA) submission to the FDA was initiated in December 2025.

Negatives

• Treatment-emergent serious adverse events (TESAEs) were reported in four patients, including left arm pain, non-cardiac chest pain, sepsis, stroke, and shoulder enthesopathy, all graded as Grade 2 or Grade 3.
• The event of shoulder enthesopathy was the only serious adverse event (SAE) deemed related to treatment.
• One patient who had withdrawn from ERT resumed ERT after more than three years, although they maintained supraphysiological α-Gal A activity and generally stable lyso-Gb3 levels.
• The 95% confidence intervals for the mean annualized eGFR slopes at both 52 weeks (-0.153, 4.083) and 104 weeks (-0.106, 3.601) included negative values, indicating some statistical uncertainty in the positive trend, despite the positive mean.

Risks

• Lack of capital resources to obtain regulatory approval for and commercialize product candidates in a timely manner or at all.
• Uncertain timing and unpredictable nature of clinical trial results, including the risk that the therapeutic effects observed in the Phase 1/2 STAAR study will not be durable in patients.
• Risk that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec.
• Risk that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene civaparvovec or support FDA approval.
• Risk that patients withdrawn from ERT will not remain off ERT.
• Need for substantial additional funding to execute the operating plan and to continue to operate as a going concern.
• Effects of macroeconomic factors or financial challenges, including as a result of ongoing overseas conflicts, tariffs, geopolitical instability, inflation, and fluctuations in interest rates, on the global business environment, healthcare systems, and business and operations.
• Risks associated with the research and development process.
• The unpredictable regulatory approval process for product candidates across multiple regulatory authorities.
• Reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any registrational trial of product candidates.
• The potential for technological developments that obviate technologies used by Sangamo.
• Reliance on collaborators and the potential inability to secure additional collaborations.
• Ability to achieve expected future financial performance.

Future Outlook

Sangamo expects isaralgagene civaparvovec to qualify for the FDA's Accelerated Approval program, with the Phase 1/2 STAAR study data serving as the primary basis for approval. The company anticipates the availability of additional data to support the Biologics License Application (BLA) submission and potentially accelerate the expected timeline to approval. They also project that the therapeutic effects observed will be durable and that patients withdrawn from ERT will remain off ERT.

Management Comments

• Sangamo announced the presentation of clinical data from its registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec for the treatment of Fabry disease.
• The company initiated a rolling submission of a Biologics License Application (BLA) to the FDA seeking approval of isaralgagene civaparvovec under an Accelerated Approval pathway.

Industry Context

StockSavvy.ai notes that gene therapies for rare genetic disorders like Fabry disease represent a significant advancement, offering the potential for a single-dose treatment to address the underlying cause of the disease, contrasting with chronic enzyme replacement therapies. The positive clinical data for isaralgagene civaparvovec, coupled with the FDA's agreement on an Accelerated Approval pathway, positions Sangamo as a key player in the competitive gene therapy landscape, potentially disrupting the existing treatment paradigm for Fabry disease.

Comparison to Industry Standards

• The positive mean annualized eGFR slopes of 1.965 mL/min/1.73m²/year at 52 weeks and 1.747 mL/min/1.73m²/year at 104 weeks compare favorably to a meta-analysis of publications of approved Fabry treatments, including Fabrazyme, Replagal, and Galafold.
• The upper confidence limit (UCL) of the 95% CI for approved therapies, -1.055 mL/min/1.73m²/year, serves as a conservative historical comparator, which the observed positive slopes for isaralgagene civaparvovec exceed, indicating a potentially superior or at least highly competitive renal benefit.
• The ability for all 18 ERT-treated patients to safely withdraw from ERT, with one patient off for over four years, demonstrates a significant advantage over existing chronic ERT treatments, which require lifelong infusions.

Stakeholder Impact

• Shareholders: Potential for significant value creation if the gene therapy receives accelerated approval and commercializes successfully, but also exposure to clinical development and commercialization risks, including the need for substantial additional funding.
• Patients with Fabry disease: Potential for a transformative, single-dose treatment that could replace chronic ERT, improve quality of life, stabilize disease progression, and reduce the burden of lifelong therapy.
• Healthcare providers: New and potentially more convenient treatment option for Fabry disease, simplifying patient management compared to chronic infusions.
• Regulatory authorities: Successful accelerated approval could further validate the pathway for other gene therapies in rare diseases, influencing future regulatory decisions.

Next Steps

• Continued monitoring of patients treated in the STAAR study for up to five years in the separate long-term follow-up study.
• Ongoing rolling submission of a Biologics License Application (BLA) to the FDA for isaralgagene civaparvovec.
• Potential FDA approval of isaralgagene civaparvovec under the Accelerated Approval Program.
• Generation of additional data, including 104-week data, to verify the clinical benefit of isaralgagene civaparvovec and support full FDA approval.

Key Dates

Recommendation

The filing presents compelling positive clinical data for isaralgagene civaparvovec, a wholly-owned gene therapy for Fabry disease, demonstrating favorable safety, sustained α-Gal A activity, eGFR improvement, and the ability for patients to withdraw from chronic ERT. The FDA's agreement on an Accelerated Approval pathway and the initiation of a rolling BLA submission significantly de-risk the regulatory path and accelerate potential market entry. While clinical development inherently carries risks, the strong interim results and regulatory clarity suggest a high probability of success and substantial upside potential for Sangamo Therapeutics, making it an attractive investment.

Keywords

Fabry disease, gene therapy, isaralgagene civaparvovec, ST-920, STAAR study, Phase 1/2, clinical data, FDA Accelerated Approval, Biologics License Application, BLA, eGFR, alpha-galactosidase A, lyso-Gb3, enzyme replacement therapy, ERT withdrawal, quality of life, cardiac function, immunogenicity, rare disease, genetic disorder, Sangamo Therapeutics